The Price War On Drugs: HCV Competition Finally Sparks Discounting
The approval of Abbvie’s Viekira Pak combination HCV therapy has touched off a round of discounting in the high-profile specialty drug arena that is likely to bleed into other existing and future competitive markets.
You may also be interested in...
Pfizer CEO Ian Read, Regeneron CEO Leonard Schleifer, Gilead CEO John Milligan and Lilly’s incoming CEO David Ricks discussed pharma’s reputation problem during the Forbes Healthcare Summit.
Nidda Healthcare, the investment vehicle controlled by Bain Capital and Cinven, has decided on a share price for the final squeeze-out of Stada’s remaining minority shareholders.
OTC marketing news from Germany: Bayer’s Talcid Liquid returns to pharmacy shelves, Stada extends its successful Probielle probiotics range and Dr Kade adds “gel” version of Riopan.